Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MASS 
908 Devices Inc (MASS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MASS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 217.24M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 4 | Beta 0.37 | 52 Weeks Range 1.81 - 8.06 | Updated Date 09/16/2025 |
52 Weeks Range 1.81 - 8.06 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.13% | Operating Margin (TTM) -64.2% |
Management Effectiveness
Return on Assets (TTM) -15.39% | Return on Equity (TTM) -53.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 87926908 | Price to Sales(TTM) 3.31 |
Enterprise Value 87926908 | Price to Sales(TTM) 3.31 | ||
Enterprise Value to Revenue 1.34 | Enterprise Value to EBITDA -3.15 | Shares Outstanding 36085700 | Shares Floating 22134967 |
Shares Outstanding 36085700 | Shares Floating 22134967 | ||
Percent Insiders 8.37 | Percent Institutions 83.39 |
Upturn AI SWOT
908 Devices Inc
Company Overview
History and Background
908 Devices Inc. was founded in 2012, focusing on mass spectrometry technology for chemical and biomolecular analysis. The company has grown by developing handheld and benchtop devices for various applications, primarily in life sciences, industrial analysis, and forensics.
Core Business Areas
- Handheld Devices: Develops and markets handheld mass spectrometry devices, like the MX908, for rapid chemical identification in the field.
- Benchtop Devices: Creates benchtop mass spectrometry devices, like the ZipChip, for laboratory analysis and research.
- Software and Consumables: Provides software, consumables, and support services related to its devices, contributing to recurring revenue.
Leadership and Structure
Mike Ramsay is the Chairman, President & CEO. The organizational structure includes functional departments such as R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- MX908: Handheld mass spectrometer used for chemical threat detection, narcotics identification, and hazmat response. Competitors include Smiths Detection and FLIR Systems. Estimated Revenue (2023): $25 million (Estimate). Market share in the handheld narcotics identification market is approximately 15%.
- ZipChip: Microfluidics separation platform coupled with mass spectrometry for rapid analysis of biomolecules. Competitors include Agilent Technologies and Thermo Fisher Scientific. Estimated Revenue (2023): $18 million (Estimate). Market share in the microfluidics separation market is approximately 5%.
Market Dynamics
Industry Overview
The analytical instrumentation market is driven by advancements in technology, increasing regulatory requirements, and growing demand for accurate and rapid analysis in various industries.
Positioning
908 Devices Inc. positions itself as an innovator in mass spectrometry, offering portable and rapid analysis solutions. Competitive advantages include device portability and speed.
Total Addressable Market (TAM)
The TAM for mass spectrometry and related analytical instruments is estimated at $7 billion. 908 Devices Inc. is positioned to capture a portion of this market with its specialized products.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Portable and rapid analysis solutions
- Strong brand reputation
- Established customer base
- Experienced management team
Weaknesses
- Limited product portfolio
- High reliance on key customers
- High production costs
- Geographic concentration of sales (North America)
- Relatively small salesforce
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing products
- Acquiring complementary technologies
- Increasing government funding for security and defense
- Partnerships with large organizations
Threats
- Competition from larger, more established companies
- Technological obsolescence
- Economic downturn
- Changes in regulatory requirements
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- KEYS
- TMO
- WAT
Competitive Landscape
908 Devices Inc. competes with larger companies with more diverse product portfolios. Its advantages lie in specialized products and speed.
Growth Trajectory and Initiatives
Historical Growth: 908 Devices Inc. has demonstrated rapid revenue growth since its IPO. Key growth drivers include expanding sales of its handheld and benchtop devices.
Future Projections: Analysts project continued revenue growth of 15-20% annually for the next 3-5 years, driven by market expansion and new product launches.
Recent Initiatives: Recent strategic initiatives include expanding its sales force, entering new markets, and developing strategic partnerships.
Summary
908 Devices Inc is an innovative company with strong growth potential in the analytical instrumentation market. Its revenue growth and improvements in its gross profit are working well for the company. However, it continues to be at a net loss, and it needs to watch out for market competition from larger competitors and technology obsolescence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- 908 Devices Inc. Annual Reports
- Analyst Reports
- Company Press Releases
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 908 Devices Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-12-18 | Co-Founder, CEO, President & Director Dr. Kevin J. Knopp Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 246 | Website https://908devices.com |
Full time employees 246 | Website https://908devices.com | ||
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling. The company's products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.